Fertility and Sterility
Volume 94, Issue 3 , Pages 888-899 , August 2010

A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial

Presented at the annual meeting of the American Society of Reproductive Medicine, Washington, D.C., October 14–17, 2007.

  • Richard H. Reindollar, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
    • Corresponding Author InformationReprint requests: Richard Reindollar, M.D., Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756 (FAX: 603-650-0906).
    • ,
  • Meredith M. Regan, Sc.D.

      Affiliations

    • Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    • ,
  • Peter J. Neumann, Sc.D.

      Affiliations

    • Center for the Evaluation of Value and Risk in Health, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Bat-Sheva Levine, M.D.

      Affiliations

    • Center for the Evaluation of Value and Risk in Health, Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts
    • ,
  • Kim L. Thornton, M.D.

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Biology, Division of Reproductive Endocrinology and Infertility, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Boston IVF, Waltham, Massachusetts
    • ,
  • Michael M. Alper, M.D.

      Affiliations

    • Department of Obstetrics, Gynecology and Reproductive Biology, Division of Reproductive Endocrinology and Infertility, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Boston IVF, Waltham, Massachusetts
    • ,
  • Marlene B. Goldman, Sc.D.

      Affiliations

    • Departments of Obstetrics and Gynecology and Community and Family Medicine, Dartmouth Medical School and Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

Received 11 March 2009 ,Revised 7 April 2009 ,Accepted 8 April 2009.

References 

  1. Fisch P, Casper RF, Brown SE, Wrixon W, Collins JA, Reid RL, et al. Unexplained infertility: evaluation of treatment with clomiphene citrate and human chorionic gonadotropin. Fertil Steril. 1989;51:828–833
  2. Glazener CM, Coulson C, Lambert PA, Watt EM, Hinton RA, Kelly NG, et al. Clomiphene treatment for women with unexplained infertility: placebo-controlled study of hormonal responses and conception rates. Gynecol Endocrinol. 1990;4:75–83
  3. Chaffkin LM, Nulsen JC, Luciano AA, Metzger DA. A comparative analysis of the cycle fecundity rates associated with combined human menopausal gonadotropin (hMG) and intrauterine insemination (IUI) versus either hMG or IUI alone. Fertil Steril. 1991;55:252–257
  4. Gürgan T, Kişnişçi H, Yarali H, Aksu T, Zeyneloğlu H, Develioğlu O. The value of human menopausal gonadotropin treatment in patients with unexplained infertility. Int J Gynaecol Obstet. 1991;35:327–330
  5. Assisted reproductive technology in the United States and Canada: 1993 results generated from the American Society for Reproductive Medicine/Society for Assisted Reproductive Technology Registry. Fertil Steril. 1995;64:13–21
  6. Deaton JL, Clark RR, Pittaway DE, Herbst P, Bauguess P. Clomiphene citrate ovulation induction in combination with a timed intrauterine insemination: the value of urinary luteinizing hormone versus human chorionic gonadotropin timing. Fertil Steril. 1997;68:43–47
  7. Guzick DS, Sullivan MW, Adamson GD, Cedars MI, Falk RJ, Peterson EP, et al. Efficacy of treatment for unexplained infertility. Fertil Steril. 1998;70:207–213
  8. Guzick DS, Carson SA, Coutifaris C, Overstreet JW, Factor-Litvak P, Steinkampf MP, et al. Efficacy of superovulation and intrauterine insemination in the treatment of infertility. National Cooperative Reproductive Medicine Network. N Engl J Med. 1999;340:177–183
  9. Gleicher N, Oleske DM, Tur-Kaspa I, Vidali A, Karande V. Reducing the risk of high-order multiple pregnancy after ovarian stimulation with gonadotropins. N Engl J Med. 2000;343:2–7
  10. Dickey RP, Taylor SN, Lu PY, Sartor BM, Rye PH, Pyrzak R. Relationship of follicle numbers and estradiol levels to multiple implantation in 3,608 intrauterine insemination cycles. Fertil Steril. 2001;75:69–78
  11. Wright VC, Chang J, Jeng G, Chen M, Macaluso M Centers for Disease Control and Prevention. Assisted reproductive technology surveillance - United States, 2004. MMWR Surveill Summ. 2007;56:1–22
  12. Neumann PJ, Gharib SD, Weinstein MC. The cost of a successful delivery with in vitro fertilization. N Engl J Med. 1994;331:239–243
  13. Callahan TL, Hall JE, Ettner SL, Christiansen CL, Greene MF, Crowley WF. The economic impact of multiple-gestation pregnancies and the contribution of assisted-reproduction techniques to their incidence. N Engl J Med. 1994;331:244–249
  14. Kinzler WL, Ananth CV, Vintzileosi AM. Medical and economic effects of twin gestations. J Soc Gynecol Investig. 2000;7:321–327
  15. te Velde ER, Eijkemans R, Habbema HD. Variation in couple fecundity and time to pregnancy, an essential concept in human reproduction. Lancet. 2000;355:1928–1929
  16. Savitz DA, Hertz-Picciotto I, Poole C, Olshan AF. Epidemiologic measures of the course and outcome of pregnancy. Epidemiol Rev. 2002;24:91–101
  17. U.S. Bureau of Labor Statistics, ftp://ftp.bls.gov/pub/suppl/empsit.ceseeb2.txt. Last accessed on December 12, 2008.
  18. Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer-Verlag; 2000;
  19. Efron B, Tibshirani RJ. An introduction to the bootstrap. Boca Raton, FL: CRC Press; 1998;
  20. Prinssen M, Buskens E, de Jong SE, Buth J, Mackaay AJ, van Sambeek MR, et al. DREAM trial participants. Cost-effectiveness of conventional and endovascular repair of abdominal aortic aneurysms: Results of a randomized trial. J Vasc Surg. 2007;46:883–890
  21. Unutzer J, Katon WJ, Fan MY, Schoenbaum MC, Lin EH, Della Penna RD, et al. Long-term cost effects of collaborative care for late-life depression. Am J Manag Care. 2008;14:95–100
  22. Graff MJ, Adang EMM, Vernooij-Dassen MJ, Dekker J, Jönsson L, Thijssen M, et al. Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study. BMJ. 2008;336:34–38
  23. Karande VC, Korn A, Morris R, Rao R, Balin M, Rinehart J, et al. Prospective randomized trial comparing the outcome and cost of in vitro fertilization with that of a traditional treatment algorithm as first-line therapy for couples with infertility. Fertil Steril. 1999;71:468–475
  24. Van Landuyt L, Verheyen G, Tournaye H, Camus M, Devroey P, Van Steirteghem A. New Belgian embryo transfer policy leads to sharp decrease in multiple pregnancy rate. Reprod BioMed Online. 2006;13:765–771
  25. Debrock S, Spiessens C, Meuleman C, Segal L, De Loecker P, Meeuwis L, et al. New Belgian legislation regarding the limitation of transferable embryos in in vitro fertilization cycles does not significantly influence the pregnancy rate but reduces the multiple pregnancy rate in a three fold way in the Leuven University Fertility Center. Fertil Steril. 2005;83:1572–1574
  26. Multiple gestation pregnancy. The ESHRE Capri Workshop Group. Hum Reprod. 2000;15:1856–1864
  27. Stern JE, Cedars MI, Jain T, Klein NA, Beaird CM, Grainger DA, et al. Assisted reproductive technology practice patterns and the impact of embryo transfer guidelines in the United States. Fertil Steril. 2007;88:275–282

 R.H.R. reports receiving fellowship training funds and lecture fees from Ferring, Organon, and Serono before 2005. M.M.R. has nothing to disclose. P.J.N. reports receiving grant support from Elan Pharmaceuticals and Johnson & Johnson, receiving consultant fees from Serono and General Electric, and serving on advisory boards for Merck, Schering Plough, and Abbott; B-S.L. reports receiving an educational grant from Novo Nordisk. K.L.T. reports receiving fellowship training support from Ferring, research grant support from Duramed, Organon, and Serono, consulting fees from Organon, and lecture fees from Organon and Serono. M.M.A. reports receiving unrestricted research grants from Serono and Organon, consulting fees from Serono, and lecture fees from Ferring, Organon, and Serono. M.B.G. has nothing to disclose.

 Supported by a grant from the National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland (R01 HD38561). The National Institute of Child Health and Human Development had no role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

 Work was performed at the Department of Obstetrics and Gynecology and Reproductive Biology, Division of Reproductive Endocrinology and Infertility, Beth Israel Deaconess Medical Center, Boston, Massachusetts; Boston IVF, Waltham, Massachusetts; and the Department of Obstetrics and Gynecology, Dartmouth Medical School, Hanover, New Hampshire.

PII: S0015-0282(09)00866-8

doi: 10.1016/j.fertnstert.2009.04.022

Fertility and Sterility
Volume 94, Issue 3 , Pages 888-899 , August 2010

Article Tools

* Image Usage & Resolution